NEW YORK (GenomeWeb) – WaveSense announced today that has signed a strategic marketing agreement with diagnostics distributor Pisces Scientific for its recently CE-IVD marked rare cell enrichment platform and bead-based isolation technology.

Under the terms of the deal, Pisces will market and sell WaveSense products — including the company's EpiSep direct-to-slide enrichment platform and its proprietary paramagnetic bead technology for the selective isolation of cells that express CD138 — to hematology-oncology cytogenetics labs in Ireland and the UK.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.